Axonics Modulation Technologies Inc.

51.20+0.3450+0.68%Vol 94.24K1Y Perf -12.27%
Jun 8th, 2023 11:41 DELAYED
BID51.15 ASK51.24
Open50.67 Previous Close50.85
Pre-Market49.92 After-Market-
 -0.93 -1.83%  - -
Target Price
82.67 
Analyst Rating
Moderate Buy 1.55
Potential %
61.99 
Finscreener Ranking
★★★★★     58.65
Insiders Trans % 3/6/12 mo.
-100/-100/-100 
Value Ranking
★★★★     55.49
Insiders Value % 3/6/12 mo.
-100/-100/-100 
Growth Ranking
★★★★     58.41
Insiders Shares Cnt. % 3/6/12 mo.
-100/-100/-100 
Income Ranking
 —    -
Price Range Ratio 52W %
13.87 
Earnings Rating
Strong Buy
Market Cap2.58B 
Earnings Date
1st May 2023
Alpha0.03 Standard Deviation0.17
Beta0.40 

Today's Price Range

50.5951.33

52W Range

46.5779.92

Summary:

Neutral

Technical Indicators: Neutral
Moving Averages: Sell
Performance
1 Week
3.12%
1 Month
-7.61%
3 Months
-6.04%
6 Months
-22.83%
1 Year
-12.27%
3 Years
29.59%
5 Years
-
10 Years
-

TickerPriceChg.Chg.%
AXNX51.200.34500.68
AAPL179.431.61000.91
GOOG123.180.24000.20
MSFT325.702.32000.72
XOM107.62-0.9076-0.84
WFC41.74-0.3350-0.80
JNJ158.960.44000.28
FB---
GE106.890.81000.76
JPM139.95-0.7400-0.53
ProfitabilityValueIndustryS&P 500US Markets
70.60
-32.00
-27.30
-3 870.40
-32.14
RevenueValueIndustryS&P 500US Markets
187.78M
3.79
295.53
-
Earnings HistoryEstimateReportedSurprise %
Q01 2023-0.34-0.1944.12
Q04 2022-0.230.01104.35
Q03 2022-0.47-0.3427.66
Q02 2022-0.57-0.4717.54
Q01 2022-0.69-0.5027.54
Q04 2021-0.36-0.345.56
Q03 2021-0.46-0.3817.39
Q02 2021-0.51-0.59-15.69
Earnings Per EndEstimateRevision %Trend
6/2023 QR-0.127.69Positive
9/2023 QR-0.1023.08Positive
12/2023 FY-0.4031.03Positive
12/2024 FY-0.0473.33Positive
Next Report Date-
Estimated EPS Next Report-0.34
Estimates Count5
EPS Growth Next 5 Years %-
Volume Overview
Volume94.24K
Shares Outstanding50.38K
Shares Float49.80M
Trades Count2.90K
Dollar Volume4.80M
Avg. Volume552.09K
Avg. Weekly Volume513.82K
Avg. Monthly Volume549.39K
Avg. Quarterly Volume593.07K

Axonics Modulation Technologies Inc. (NASDAQ: AXNX) stock closed at 50.85 per share at the end of the most recent trading day (a 3.42% change compared to the prior day closing price) with a volume of 628.71K shares and market capitalization of 2.58B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 302 people. Axonics Modulation Technologies Inc. CEO is Raymond Wayne Cohen.

The one-year performance of Axonics Modulation Technologies Inc. stock is -12.27%, while year-to-date (YTD) performance is -18.68%. AXNX stock has a five-year performance of %. Its 52-week range is between 46.57 and 79.915, which gives AXNX stock a 52-week price range ratio of 13.87%

Axonics Modulation Technologies Inc. currently has a PE ratio of -36.40, a price-to-book (PB) ratio of 5.38, a price-to-sale (PS) ratio of 14.51, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -13.64%, a ROC of -14.09% and a ROE of -15.66%. The company’s profit margin is -32.14%, its EBITDA margin is -27.30%, and its revenue ttm is $187.78 Million , which makes it $3.79 revenue per share.

Of the last four earnings reports from Axonics Modulation Technologies Inc., there were 4 positive earnings surprise and 0 negative earnings surprise. The company has EPS estimate of $-0.34 for the next earnings report. Axonics Modulation Technologies Inc.’s next earnings report date is -.

The consensus rating of Wall Street analysts for Axonics Modulation Technologies Inc. is Moderate Buy (1.55), with a target price of $82.67, which is +61.99% compared to the current price. The earnings rating for Axonics Modulation Technologies Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Axonics Modulation Technologies Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Axonics Modulation Technologies Inc. has a Neutral technical analysis rating based on Technical Indicators (ADX : 9.41, ATR14 : 1.98, CCI20 : -29.58, Chaikin Money Flow : -0.16, MACD : -1.61, Money Flow Index : 25.96, ROC : 1.03, RSI : 47.23, STOCH (14,3) : 51.58, STOCH RSI : 1.00, UO : 52.49, Williams %R : -48.42), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Axonics Modulation Technologies Inc. in the last 12-months were: Alfred J. Ford (Option Excercise at a value of $486 817), Alfred J. Ford (Sold 36 015 shares of value $2 391 415 ), Cohen Raymond (Sold 44 000 shares of value $3 099 351 ), Danny L. Dearen (Option Excercise at a value of $1 810 769), Danny L. Dearen (Sold 225 314 shares of value $15 039 386 ), Esteban Lopez (Sold 2 000 shares of value $134 840 ), Jane E. Kiernan (Sold 5 250 shares of value $315 000 ), John Woock (Option Excercise at a value of $550 904), John Woock (Sold 45 215 shares of value $3 159 579 ), Karen Noblett (Option Excercise at a value of $623 335), Karen Noblett (Sold 32 483 shares of value $2 538 799 ), Kiernan Jane (Sold 5 250 shares of value $315 000 ), Raymond Wayne Cohen (Sold 84 736 shares of value $5 785 326 ), Rinda Sama (Sold 36 415 shares of value $2 241 166 ), Sama Rinda (Sold 0 shares of value $-576 872 ), Sama Rinda (Sold 70 265 shares of value $4 596 018 ), Woock John (Sold 0 shares of value $-12 225 ), Woock John (Sold 22 500 shares of value $1 592 771 )

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
5 (50.00 %)
5 (55.56 %)
4 (50.00 %)
Moderate Buy
4 (40.00 %)
3 (33.33 %)
2 (25.00 %)
Hold
1 (10.00 %)
1 (11.11 %)
2 (25.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.55
Strong Buy
1.50
Moderate Buy
1.69

Axonics Modulation Technologies Inc.

Axonics Modulation Technologies Inc is a United stated based medical technology company. It focuses on the design, development, and commercialization of innovative and minimally invasive sacral neuromodulation (SNM) solutions. SNM therapy is primarily used to treat patients with overactive bladder, fecal incontinence, and urinary retention. The company has designed and developed the r-SNM System, which delivers mild electrical pulses to the targeted sacral nerve in order to restore normal communication to and from the brain to reduce the symptoms of overactive bladder and fecal incontinence.

CEO: Raymond Wayne Cohen

Telephone: +1 949 396-6322

Address: 26 Technology Drive, Irvine 92618, CA, US

Number of employees: 302

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

0%100%

Bearish Bullish

50%50%

Bearish Bullish

55%45%

Bearish Bullish

60%40%

 

TipRanks News for AXNX

Mon, 01 May 2023 17:15 GMT Axonics Modulation Technologies (AXNX) Receives a Buy from Mizuho Securities

- TipRanks. All rights reserved.

News

Stocktwits